EUCTR2015-000809-39-FR进行中（未招募）1 期
An Open-label, Multicenter, Expanded Access Program for Asfotase Alfa (human recombinant tissue-nonspecific alkaline phosphatase fusion protein) Treatment for Patients with Infantile- or Juvenile-onset Hypophosphatasia (HPP)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must meet all of the following inclusion criteria to be eligible for participation in this program:
- •1.Parent or legal guardian must provide written informed consent prior to the performance of any program-related procedures and must be willing to comply with program procedures. Where appropriate and required by local regulations, patient assent for participation must also be obtained.
- •2.Patient must have a documented diagnosis of HPP as indicated by a documented history of HPP-related skeletal abnormalities and one or more of the following:
- •Documented tissue-nonspecific alkaline phosphatase (TNSALP) gene mutation(s)
- •Serum alkaline phosphatase (ALP) level below the age-adjusted normal range AND plasma pyridoxal-5’-phosphate (PLP) above the upper limit of normal at Screening.
- •3.Patient must have infantile- or juvenile-onset HPP, defined as documented onset of signs/symptoms of HPP prior to 18 years of age.
- •4.Male patient is:
- •Prepubertal; OR
- •Surgically sterile (defined as vasectomized for =6 months at Baseline); OR
- •Non-surgically sterile (defined as non-vasectomized or vasectomized for <6 months at Baseline) and his female spouse/partner who is of childbearing potential must be using highly effective contraception consisting of two forms of birth control (at least one of which must be a barrier method) as described below starting at Baseline and continuing for 3 months after program completion.
- •- Simultaneous use of condom, and for the female partner established use of hormonal contraceptives (eg, oral, injected, implanted) or intra-uterine contraceptive device
- •- Simultaneous use of condom, and for the female partner occlusive cap (diaphragm or cervical/vault caps) with intravaginally applied spermicide5.Patient must have infantile- or juvenile-onset HPP, defined as documented onset of signs/symptoms of HPP prior to 18 years of age.
- •5.Female patient is:
- •Of non-childbearing potential, defined as:
- •- Prepubertal; OR
- •- Post-menopausal (defined as absence of menses for 12 months prior to Baseline or bilateral oophorectomy or hysterectomy with bilateral oophorectomy at least 6 months prior to Baseline); OR
- •- Surgically sterile (defined as having hysterectomy or tubal ligation at least 6 months prior to Baseline)
- •Of childbearing potential, and:
- •- Not sexually active; OR
- •- Sexually active with non-sterile male spouse/partner (sterile male spouse/partner defined as a man vasectomized for =6 months) and must be using highly effective contraception consisting of two forms of birth control (at least one of which must be a barrier method) as described below and continuing for 3 months after program completion.
- •- Simultaneous use of hormonal contraceptives (eg, oral, injected, implanted) or intrauterine contraceptive device since at least 4 weeks prior to Baseline, and condom for the male partner
- •- Simultaneous use of occlusive cap (diaphragm or cervical/vault caps) with
- •intravaginally applied spermicide,
- •6. Male patients who are pubertal or post-pubertal and not surgically sterile (surgically sterile defined as vasectomized for =6 months) must agree to not donate sperm during program participation and for 3 months after program completion.
- •7.Female patients of childbearing potential (ie, those who are not prepubertal or post-menopausal or surgically sterile as defined in inclusion criteria 5 above) must have a negative urine or serum pregnancy test at Screening.
- •Are the trial subjects under
排除标准
- •Patients will be excluded from participation in this program if they meet one or more of the following exclusion criteria:
- •1.Patient has geographic access to and qualifies for enrollment (as determined by the Sponsor and Investigator) in any other Alexion-sponsored clinical trials of asfotase alfa that are open to enrollment (eg, ENB-010-10).
- •2.Patient is pregnant, trying to become pregnant, or is lactating.
- •3.Patient has a documented sensitivity to any of the components of asfotase alfa.
- •4.Patient has serum calcium and/or phosphorus levels below the normal range at Screening.
- •5.Patient is currently enrolled in any other program or study involving an investigational new drug, device, or treatment for HPP (eg, bone marrow transplantation).
- •6.Patient has any other medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with program compliance, including all evaluations and follow-up activities.
研究者
相似试验
进行中（未招募）
不适用
An expanded access program of ranibizumab in patients with visual impairment due to diabetic macular edema for whom no suitable therapeutic alternatives exist.EUCTR2011-002731-26-ITOVARTIS FARMA700
进行中（未招募）
不适用
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Commercially Available TherapiesEUCTR2009-017671-22-BEEisai Limited500
已完成
Unknown
Trastuzumab deruxtecan for subjects with HER2 mutated metastatic NSCLCJPRN-jRCT2071220096eno Shizuko30
未知
不适用
STUDY TO ASSESS THE SAFETY OF RO5185426 IN PATIENTS WITH METASTATIC MELANOMAPER-001-12F. HOFFMANN-LA ROCHE LTD.,5
已完成
4 期
A Global Expanded Access Program for Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (EV-902)JPRN-jRCT2031210099Steinberg Joyce350